Jane Street Group LLC Takes $29,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL)

Jane Street Group LLC purchased a new position in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 14,759 shares of the company’s stock, valued at approximately $29,000.

A number of other hedge funds also recently modified their holdings of the stock. Foundations Investment Advisors LLC increased its position in Cardiol Therapeutics by 237.4% in the third quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company’s stock worth $321,000 after buying an additional 113,950 shares during the last quarter. Lion Street Advisors LLC lifted its position in shares of Cardiol Therapeutics by 7.9% during the 3rd quarter. Lion Street Advisors LLC now owns 273,281 shares of the company’s stock valued at $544,000 after buying an additional 20,000 shares during the last quarter. Townsquare Capital LLC bought a new position in shares of Cardiol Therapeutics during the 3rd quarter worth $27,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Cardiol Therapeutics in the 3rd quarter worth about $27,000. Institutional investors own 12.49% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a report on Wednesday, December 18th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $8.75.

Cardiol Therapeutics Trading Down 1.6 %

NASDAQ:CRDL opened at $1.21 on Friday. Cardiol Therapeutics Inc. has a 1 year low of $0.96 and a 1 year high of $3.12. The stock’s fifty day moving average price is $1.47 and its two-hundred day moving average price is $1.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49. The company has a market cap of $98.86 million, a P/E ratio of -3.10 and a beta of 0.89.

Cardiol Therapeutics Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.